Montelukast Normon (Montelukast)

Montelukast selectively antagonizes the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from triggering bronchoconstriction, mucus secretion, and inflammatory cell recruitment. This results in improved airway patency and reduced allergic inflammation.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for montelukast in pregnancy and lactation are limited. Prescribers weigh potential benefits against possible risks before recommending use. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting β2‑agonists. It is particularly useful for patients with allergic components or those who experience exercise‑induced bronchoconstriction, but it does not replace rescue bronchodilators for acute attacks.

Montelukast Normon tablets should be stored at room temperature, below 25 °C, in the original packaging. Protect them from moisture, direct sunlight and excessive heat to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include rare allergic reactions such as angioedema or severe skin eruptions, and neuropsychiatric events like depression, anxiety, or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast or any component of the formulation. Caution is advised for patients with severe hepatic impairment or those taking interacting medications listed under major interactions.